<DOC>
	<DOCNO>NCT01919671</DOCNO>
	<brief_summary>The purpose study assess effect improve life self-care ability stroke patient take Tongxinluo Capsule ( within 72 hour onset ) versus Placebos 90 day .</brief_summary>
	<brief_title>Tongxinluo Capsule Ischemic Stroke Patients（TISS )</brief_title>
	<detailed_description>The study randomize , double-blind , placebo control , multi-center trial . We aim enroll total 1968 individual ( 984 case group ) acute ischemic stroke le 72 hour onset . Participants randomize Tongxinluo capsule treatment group capsule administration 4 granule tid . 90 day , patient control group receive placebo capsule . NIH Stroke Score subject 4-22 randomization . Evaluations efficacy safety take baseline , 7 day , discharge date 90 day . Neuroimaging [ magnetic resonance imaging ( MRI ) scan ] obtain baseline 90 day therapy . The primary efficacy endpoint proportion Modified Rankin Scale ( mRS ) ≤1 90 day .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Ischemic stoke within 72 onset , confirm MRI CT. Age 3575 year , inclusive . Patients first attack patient stroke history ( modify Rankin Scale score 01 ) . Clear sign localization nervous system , NIHSS score 4 22 . Patient proxy sign informed consent . Hemorrhage diseases accord head CT MRI , hemorrhagic stroke , epidural hematoma , intracranial hematoma , intraventricular hemorrhage , subarachnoid hemorrhage , haemorrhage cerebral infarction . Transient Ischemic Attack ( TIA ) . Severe disturbance consciousness : 1a NIHSS score &gt; 1 point ; Difficulty swallowing , unable take oral capsule ; 5a , 5b , 6a , 6b NIHSS score &gt; 2 point . Convinced stroke cause brain tumor , brain trauma , hemopathy , etc . Hemorrhagic tendency patient . Patients endovascular treatment onset stroke . Patients dementia , severe Parkinson 's disease , mental disorder , limb dysfunction cause disease condition may affect therapeutic efficacy . Uncontrolled hypertension ( ≥200 mmHg systolic ≥110 mmHg diastolic ) hypotension ( ≤90 mmHg systolic ≤60mmHg diastolic ) ; severe hyperglycemia ( blood glucose ≥400 mg/dl ) hypoglycemia ( blood glucose≤50 mg/dl ) . Severe hepatic insufficiency define transaminase value &gt; 2x upper limit normal ; severe renal insufficiency define value serum creatinine &gt; 1.5x upper limit normal ; cardiac dysfunction serious systemic disease life expectancy ≤3 month . Patients concurrent malignancy ongoing antitumor therapy . Patients history allergic trial medicine . Pregnancy , breastfeed potential pregnancy . Within three month currently participate another investigational study . Any condition opinion investigator preclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Tongxinluo capsule</keyword>
</DOC>